Poseida Therapeutics Inc

Poseida Therapeutics — Investor Day (November 2024)

73 slides from Poseida Therapeutics's investor day presentation, Nov 14, 2024

  1. Slide 1: Cell Therapy R&D Day

    Exhibit 99.2 Cell Therapy R&D Day Differentiated Allogeneic Cell Therapies in Oncology and Autoimmune Disease NOVEMBER 14, 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation and any accompanying oral commentary contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, without limitation, stat

  3. Slide 3: Introduction: Poseida poised to lead in allogeneic cell therapy

    Introduction: Poseida poised to lead in allogeneic cell therapy Kristin Yarema, PhD President & CEO

  4. Slide 4: Agenda and executive and scientific leadership

    Introduction: Poseida poised to lead in allogeneic cell therapy Kristin Yarema, PhD Heme malignancies: P-BCMA-ALLO1 leads a portfolio of allogeneic T -rich CAR-T programs SCM Syed Rizvi, MD From hematology to autoimmune disease: Poseida’s BCMA-CD19 dual CAR-T Kurinji Pandiyan, PhD Waves of innovatio

  5. Slide 5: On a mission to advance a new class of cell therapies & genetic medicines

    On a mission to advance a new class of cell therapies & genetic medicines GENETIC MEDICINES ALLOGENEIC CAR-T Non-viral delivery for gene Enabling broad and rapid “Top 10 Public Gene Therapy insertion and gene editing patient access to Company” to meet patient needs transformational CAR-T “Top 10 Pub

  6. Slide 6: Our unique system of non-viral tools

    Our unique system of non-viral tools can be used individually or together – with the capacity to treat cancer, autoimmune and rare diseases POSEIDA SYSTEM OF NON-VIRAL TOOLS + Cas-CLOVER Transposon-based Enabling Gene Editing DNA insertion technologies NON-VIRAL GENETIC MEDICINES ALLOGENEIC CAR-T No

  7. Slide 7: Platform underpins work in three cell therapy areas

    Poseida’s robust platform underpins and enables work in three cell therapy areas Areas of unmet need poised for disruption with the right allogeneic CAR-T platform Opportunity Hematology 200K New U.S. patients per year, Despite auto CAR-T approvals, access heavily representing ~10% of all new restri

  8. Slide 8: Full set of capabilities needed for success in allogeneic cell therapy

    Poseida has built a full set of capabilities needed for success in allogeneic cell therapy OTHERS POSEIDA SYSTEM POSEIDA ADVANTAGE • Product profile unique in • Differentiated T cells • T stem cell memory cells 'stemness’ CELL TYPE • Variety of other immune (T ) SCM • Expected better safety cell typ

  9. Slide 9: Proprietary toolkit to produce T SCM-rich allogeneic CAR-T

    Our unique and proprietary toolkit has the capabilities required to produce T -rich SCM allogeneic CAR-T, with potential to drive depth and durability of response Fully Non-Viral Approach Transposon Quality Enabling Tech Cas-CLOVER 1 2 3 Non-viral gene Gene editing manufacturing at insertion system

  10. Slide 10: Rich pipeline of partnered and wholly-owned programs

    Our rich pipeline includes partnered and wholly-owned allogeneic CAR-T as well as non-viral genetic medicines INDICATION PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 Heme Malignancies and Autoimmune Diseases Multiple myeloma P-BCMA-ALLO1 B-cell malignancies P-CD19CD20-ALLO1 Multiple myeloma and P-BCMACD

  11. Slide 11: Path to value creation in allogeneic cell therapy

    Poseida’s path to value creation in allogeneic cell therapy Presently heading into our second growth horizon Disrupt Cell Extend Therapy Approach Build Foundation DELIVER FOR PATIENTS DRIVE VALUE • Stream assets from allogeneic CAR- VALIDATE PLATFORM T product engine SCM • Enter autoimmune disease s

  12. Slide 12: Heme malignancies: P-BCMA-ALLO1 leads a portfolio of allogeneic CAR-T programs

    Heme malignancies: P-BCMA-ALLO1 leads a portfolio of allogeneic T -rich CAR-T programs SCM Syed Rizvi, MD Chief Medical Officer

  13. Slide 13: Investigator quote on rapid responses and safety

    Right off the bat, I was very impressed with the “ rapid responses we saw in a couple of initial patients we treated, including several patients of my colleagues who had failed other standard therapies, including a significant amount of extramedullary disease. And within 4 to 6 weeks, the disease me

  14. Slide 14: Investigator quote on overall response rate

    I was very impressed with the overall “ response rate. The overall response rate in the patients who were BCMA naive was 100%, and the overall response rate in patients who were BCMA exposed was 86%. KEY OL QUOTES FROM FIRESIDE CHAT And even in the seven patients who had exposure to BCMA and talquet

  15. Slide 15: P-BCMA-ALLO1 first-in-kind allogeneic CAR-T for multiple myeloma

    P-BCMA-ALLO1 is a first-in-kind allogeneic CAR-T for multiple myeloma MM is a common and incurable FDA Regenerative Medicine blood cancer, with ~12,500 Advanced Therapy (RMAT) and 1 P-BCMA-ALLO1 estimated U.S. deaths in 2024 Orphan Drug Designation (ODD) Anti-BCMA CAR ~179,000 people living with Hea

  16. Slide 16: Allogeneic approach simplifies patient access to CAR-T

    An allogeneic approach can greatly simplify and enable patient access to transformational CAR-T PATIENT RESPONSE 30 DAYS AFTER TREATMENT TREATMENT 1 DECISION INFUSION INITIATION WEEKS to MONTHS AUTOLOGOUS PATIENT JOURNEY SCHEDULE POTENTIAL BRIDGING PATIENT CELL SHIPMENT PATIENT FOR NEED FOR THERAPY

  17. Slide 17: P-BCMA-ALLO1 Phase 1: Background and methods

    P-BCMA-ALLO1 Phase 1: Background and methods Phase 1, open-label, dose escalation study in patients with relapsed/refractory multiple myeloma • Must have had ≥ 3 prior lines of therapy including a PI, IMiD & • Primary Objectives: Safety and MTD/RDE CD38 mAb or be triple refractory • Secondary Object

  18. Slide 18: Clinically active in BCMA-naive and BCMA-experienced patients

    P-BCMA-ALLO1 is highly clinically active in BCMA-naïve and BCMA-experienced patients PR VGPR CR sCR 100% 100% 91% 86% 86% 82% 80% 60% 40% 20% 00% Arm C Arm C Arm C Arm C Arm C (n = 23) BCMA-naïve ≥ 1 prior BCMA ≥ 1 prior BCMA and Prior Bispecific*** (n=9*) (n=14*) GPRC5D** (n=7*) (n=11*) Arm ORR= sC

  19. Slide 19: Higher risk, more refractory patient population

    P-BCMA-ALLO1 Phase 1: A higher risk, difficult to treat and more refractory patient population* 5 6 2 3 4 KarMMa Cartitude-1 MajesTEC-1 MonumenTAL-1 MagnetisMM-3 P-BCMA-ALLO1 P-BCMA-ALLO1 Idecel Ciltacel Elranatamab 1 1 Talquetamab Teclistamab all patients arm C N=128 N=97 N=165 N=130 N=123 N=72 N=2

  20. Slide 20: Safety and efficacy versus marketed autologous CAR-T

    P-BCMA-ALLO1 early safety and efficacy results appear encouraging in comparison with marketed autologous CAR-T therapies* Safety Efficacy 1 2 Late-line ABECMA CARVYKTI P-BCMA- Late-line MM ABECMA CARVYKTI P-BCMA-ALLO1 1 2 MM Patients ALLO1 (Arm C) Patients (ITT) (ITT) (ARM C) Safety Pop N=349 N=285

  21. Slide 21: Safety and efficacy versus marketed bispecifics

    P-BCMA-ALLO1 early safety and efficacy results appear encouraging in comparison with marketed bispecific therapies* Safety Efficacy 1 2 3 Late-line TALVEY TECVAYLI ELFREXIO P-BCMA- Late-line TALVEY TECVAYLI ELREXFIO P-BCMA- 1 2 3 MM Patients ALLO1 MM (ITT) (ITT) (ITT) ALLO1 (Arm C) Patients (ARM C)

  22. Slide 22: Targets mutations arising after prior anti-BCMA therapies

    NEW P-BCMA-ALLO1 effectively targets mutations that are known to arise in patients DATA with relapse after prior anti-BCMA therapies P-BCMA-ALLO1 kills tumor cells expressing wild type BCMA or clinically identified BCMA escape mutants BCMA P33Del BCMA P33S BCMA S30Del BCMA WT BCMA R27P 4 4 4 3 3 3 3

  23. Slide 23: Response in disease markers; median time to response and duration

    Patients across Arms A, B, and C show response in disease markers, with encouraging early mTTR and mDOR a Percent Change by Subject, Color-Coded by Group Median Time to Median Duration of Response Response for Patients Groups Arm A Arm B Arm C with > 6 Months of (Pooled Arms A + B) Follow Up 0 (Pool

  24. Slide 24: Summary of P-BCMA-ALLO1 early efficacy and safety

    Summary: P-BCMA-ALLO1 demonstrates compelling early efficacy and safety results in heavily pretreated patients while delivering on the patient experience promise High efficacy (ORR) in BCMA-naive Compelling Emerging Safety Superior Patient Experience 1 2 and BCMA-experienced patients Results • ORR i

  25. Slide 25: Phase 1b study schema

    Phase 1b study schema, dose expansion is actively enrolling two dosing cohorts Phase 1/1b, open-label, dose expansion study in patients with relapsed/refractory multiple myeloma Key Inclusion: • Primary Endpoints: ORR based on IMWG criteria • Secondary Endpoints: Safety, tolerability and efficacy of

  26. Slide 26: P-CD19CD20-ALLO1 first dual CAR-T with Roche

    P-CD19CD20-ALLO1 – Poseida’s first dual CAR-T is being developed in partnership with Roche Differentiated, carrying 2 full length CARs 1 and other Poseida platform elements • Relapse due to target escape remains a common problem Preclinical data planned CD19 in B-cell malignancies CD20 MHC I for ASH

  27. Slide 27: P-CD19CD20-ALLO1 potent against dual-positive B-cell malignancies

    NEW P-CD19CD20-ALLO1 is a potent CAR-T product against CD19- and CD20-dual DATA positive B-Cell malignancies • High in vitro potency against CD19- and CD20-positive Raji model • High in vivo antitumor efficacy across CAR-T lots produced from multiple healthy donors and dose levels In vitro potency I

  28. Slide 28: Prevents relapse due to antigen escape

    NEW P-CD19CD20-ALLO1 may prevent relapse due to antigen escape by DATA targeting single-positive tumor cells • P-CD19CD20-ALLO1 shows dose-dependent and high tumor control in two in vivo models of antigen escape Raji CD19 KO (CD20+) Raji CD20 KO (CD19+) 11 11 10 10 PBS (no CAR-T) PBS (no CAR-T) 10 1

  29. Slide 29: Killing of B cells from autoimmune patient PBMCs

    NEW P-CD19CD20-ALLO1: Robust killing of B cells from primary human DATA autoimmune PBMCs • P-CD19CD20-ALLO1 assayed for cytotoxicity against B cells in primary human PBMCs from autoimmune patients (RA, SLE, MS) ⎯ Average of 3 lots of P-CD19CD20-ALLO1 (3 unique donors) • Robust depletion of B cells i

  30. Slide 30: P-CD70-ALLO1: IND-enabling asset

    P-CD70-ALLO1: Introducing an IND-enabling stage asset with multi-indication potential, including in heme malignancies and solid tumors TCR KO Partial B2M KO CD70 knockdown Key features Novel allogeneic, T -rich CD70-targeting CAR-T engineered for potency, SCM safety, and manufacturability • Unique s

  31. Slide 31: CD70 an attractive antigen target for CAR-T

    CD70 is an attractive antigen target for CAR-T, given expression levels as well as early clinical evidence in solid and liquid tumors Solid tumors CD70 expression seen across tumor types Liquid tumors AML Lymphomas Flieswasser T et al, 2019 Perna F et al. 2017 Early clinical validation of CD70 exist

  32. Slide 32: shRNA-mediated CD70 knockdown yields optimal in vivo potency

    NEW Poseida approach using robust shRNA-mediated depletion (knockdown) of DATA CD70 yields CAR-T with optimal in vivo potency Superior to CD70 knockout through gene editing Highly efficient knockdown of CD70 in Robust in vivo activity against AML models CAR-T cells using shRNA 98 shRNA KO 193 WT 1,9

  33. Slide 33: P-CD70-ALLO1 anti-AML effect with no HSC toxicity

    NEW DATA P-CD70-ALLO1 exhibits robust anti-AML effect in vivo with no HSC toxicity P-CD70-ALLO1 has robust in vivo potency against Healthy donor HSC are killed by c-Kit & CD123 CAR- CD70+ AML Nomo-1 xenograft T, but not by P-CD70-ALLO1 or control PSMA CAR-T Nomo-1 150 12 10 PBS Control Threshold 11

  34. Slide 34: From hematology to autoimmune disease: BCMA-CD19 dual CAR-T

    From hematology to autoimmune disease: Poseida’s BCMA-CD19 dual CAR-T Kurinji Pandiyan, PhD Vice President, Portfolio & Strategy

  35. Slide 35: CAR-T in autoimmune disease: promise and new questions

    CAR-T and related immunotherapies show great promise and present new questions in autoimmune disease 2021 2022 – 2024 Today’s questions Best therapeutic Optimal • Seminal results from Georg Schett • Rapid pivot of oncology / cell modality? safety? group sparked explosive interest therapy companies,

  36. Slide 36: T SCM-based platform well-suited to autoimmune disease

    Poseida’s clinically validated T -based platform is well-suited to autoimmune SCM disease applications DE SI RED P R OF I L E OF I M M UN O TH ERA P Y P OSEI D A F OR A UT OI M M UN E DI SE A SE P L ATF ORM F E ATURE S ü Clinical validation of CAR-T through oncology work SCM • Deep depletion of B ce

  37. Slide 37: P-BCMACD19-ALLO1 for autoimmune disease and heme malignancies

    P-BCMACD19-ALLO1 (IND-enabling stage): Poseida’s wholly owned investigational therapy for autoimmune disease and hematological malignancies P-BCMACD19-ALLO1 • Potent cytotoxicity against BCMA and CD19, a key feature for both autoimmune disease and in oncology given cells that need to be targeted • K

  38. Slide 38: Robust killing of B cells across autoimmune diseases

    AUTOIMMUNE DISEASE NEW DATA P-BCMACD19-ALLO1: Robust killing of B cells across multiple autoimmune diseases In vitro proof-of-concept in autoimmune disease Rheumatoid Arthritis PBMCs Systemic Lupus Erythematosus PBMCs Multiple Sclerosis PBMCs 200 200 200 E:T 1:1 E:T 5:1 E:T 1:1 E:T 5:1 E:T 1:1 E:T 5

  39. Slide 39: Depletes primary human B cells in humanized mouse model

    AUTOIMMUNE DISEASE NEW DATA P-BCMACD19-ALLO1 depletes primary human B cells in humanized mouse model In vivo proof-of-concept of robust B cell depletion PBS control Dose level 3 Dose level 2 Dose level 1 800 800 800 800 600 600 600 61% depleted 600 83% depleted 77% depleted 400 400 400 400 200 200 2

  40. Slide 40: Potential across growing autoimmune disease needs

    Immense potential of P-BCMACD19-ALLO1 to address growing needs across autoimmune diseases Illustrative examples, not exhaustive Deeper, more durable response, potential in diseases with emerging Plasma cell and B cell targeting have strong mechanistic relevance CAR-T efficacy Myasthenia Gravis 70K L

  41. Slide 41: Eliminates BCMA+ myeloma and CD19+ progenitor cells

    ONC OL OG Y NEW DATA P-BCMACD19-ALLO1 effectively eliminates BCMA+ multiple myeloma bulk tumor cells and CD19+ bone marrow progenitor cells Progenitor killing with CD19+ targeting Potent killing of MM cell lines with BCMA+ targeting - + BCMA CD19 progenitors (primary patient samples, n=4) MM patient

  42. Slide 42: Tandem BCMA binder active against wild-type and escape mutants

    ONC OL OG Y NEW DATA Tandem BCMA binder has equal activity against wild-type (WT) BCMA & identified clinical escape mutants, including teclistamab-associated mutation R27P BCMA tandem binder effectively binds BCMA mutant Potent cytotoxicity against WT & BCMA mutant cells BCM BCM A R2 A R2 7P 7 (m P

  43. Slide 43: Waves of innovation in solid tumor cell therapy

    Waves of innovation in solid tumor cell therapy Devon J. Shedlock, PhD CSO, Cell Therapy

  44. Slide 44: Solid tumors pose unique challenges for development

    Solid tumors pose unique challenges for development, requiring bold innovations to overcome and address significant unmet need No CAR-Ts approved for solid tumors* Key roadblocks 90% 1.8M of cancers are Estimated 1 1 solid tumors incidence (U.S.) CAR-T Cell Tracking & Antigen Heterogeneity Infiltrat

  45. Slide 45: Flexible platform sets up waves of innovation in solid tumors

    Poseida’s flexible platform sets up waves of innovation in allogeneic cell therapy for solid tumors, including entirely new platforms First Generation Second Generation Third Generation P-MUC1C-ALLO1 P-PSMA-ALLO1 CAR-TCR Platform Prostate cancer Pan-solid tumor Platforms may be advantageous across c

  46. Slide 46: P-MUC1C-ALLO1 lead solid tumor allogeneic CAR-T program

    F I RST G ENER AT I ON P-MUC1C-ALLO1 is Poseida’s lead solid tumor allogeneic CAR-T program P-MUC1C-ALLO1 Motivation Exploit (MTX) resistance of Poseida's CAR-T for unique, additive LD strategy • High unmet medical need in many epithelial cell-derived tumors 150 P-MUC1C-ALLO1 • Poseida’s earlier aut

  47. Slide 47: Tumor size decrease and prolonged stable disease in appendiceal carcinoma

    F I RST G ENER AT I ON NEW DATA Substantial tumor size decrease and prolonged stable disease (~1 year) in patient with heavily pretreated appendiceal carcinoma Baseline Day 344 st 1 P-MUC1C-ALLO1 Dose Screening nd 2 Dose Baseline -39 -6 0 STUDY DAY 85 st nd LD – 1 Dose LD – 2 Dose 2 2 Cy 500 mg/m Cy

  48. Slide 48: P-PSMA-ALLO1 for prostate cancer

    SECOND GENERATION NEW DATA P-PSMA-ALLO1 builds upon Poseida’s earlier PSMA autologous CAR-T program to tackle prostate cancer Multiple cell expansion and potency enhancements to deliver best product profile • Dual CAR format has shown KO for safety and improved efficacy compared to New process immun

  49. Slide 49: Dual CAR P-PSMA-ALLO1 outperformed single and tandem CAR-Ts

    ** SECOND GENERATION NEW DATA Fully dual CAR P-PSMA-ALLO1 outperformed single and tandem binder CAR-Ts In vivo screen of PSMA binder candidates Reactivity of Lead Dual CAR with PSMA isoforms PBS Control 45 CD8+ VHCAR1 40 1,500 CD4+ VHCAR2 35 Tandem VHCAR1-VHCAR2 30 1,250 Tandem VHCAR2-VHCAR1 25 Dual

  50. Slide 50: Xyphos/Poseida collaboration for convertible Allo CAR-T

    SECOND GENERATION Concept of Xyphos/Poseida Research collaboration for convertible Allo CAR-T SCM Allogeneic T SCM TM endoTCR KO Combine the Allo-T and ACCEL platform to target solid tumors MHCI KO Xyphos’ Poseida’s TM ACCEL Platform Allo-T cell platform TM CAR w/ MicAbody library αβTCR T Cell Engag

  51. Slide 51: Allogeneic universal cCAR-T and MicAbody compatibility

    SECOND GENERATION NEW DATA TM Allogeneic universal cCAR-T and solid tumor-targeting MicAbody demonstrate compatibility of Poseida, Xyphos platforms TM Allogeneic iNKG2D CAR-T + Target 1 MicAbody in vitro cell killing assay (5:1 E:T ratio) • Allogeneic universal iNKG2D 120 cCAR-T in the presence of S

  52. Slide 52: Next-generation improvements for solid tumors

    T H IR D G ENER AT ION Poseida is systematically exploring next-generation improvements for solid tumors to be used in ‘third-wave’ innovation Potency and persistence Armoring • Cell health, cell activation, • Armoring can block TME and pathway utilization for suppressive signals or co-opt maintenan

  53. Slide 53: Combination CAR-TCR technology for tough tumors

    T H IR D G ENER AT ION A new platform for tough tumors: Poseida’s combination CAR-TCR technology is designed to address the challenges of adoptive cell therapy for solid tumors • Inclusion of one or more CARs and TCRs simultaneously (CAR-TCR Allogeneic T SCM technology) is enabled by large transposo

  54. Slide 54: CAR-TCR T cells exhibit strong functional capabilities

    T H IR D G ENER AT ION CAR-TCR T cells exhibit strong functional capabilities against both cell surface CAR target and intracellular TCR target Allo CAR + abTCR or CAR + gdTCRTs kill single and double-Ag positive tumor cells When exposed to double Ag+ cells, a higher % of Allo CAR + MUC1C CAR + NY-E

  55. Slide 55: T cell engager reactivation and redirection of CAR-Ts

    Originally presented at SOHO/LLM T H IR D G ENER AT ION Inspirational case study: T cell engager reactivation and redirection of CAR-Ts This case study demonstrates the remarkable potential of T TCE talquetamab caused dramatic benign P-BCMA-101 “ reactivation years after CAR-T administration stem ce

  56. Slide 56: CAR-TCR+TCE approach in allogeneic cell therapy

    T H IR D G ENER AT ION Designing the CAR-TCR+TCE approach to work in allogeneic cell therapy: T cell engager reactivation and redirection of TCR+ CAR-Ts CAR+TCR-T synergized with TCE to control tumors expressing three unique antigens Patent filed 3 3×10 3 2.5×10 TCE No Treatment 3 CD70 2×10 αβTCR+CA

  57. Slide 57: The power of partnerships fireside chat

    The power of partnerships fireside chat Karen Basbaum Peter Sandor, MD SVP, Business Development EVP, Head of Corporate Strategy at Poseida Therapeutics at Astellas Pharma

  58. Slide 58: In-house GMP manufacturing capabilities

    In-house GMP manufacturing capabilities Loren Wagner Chief Operations Officer

  59. Slide 59: In-house GMP allogeneic CAR-T manufacturing for higher yields and lower COGS

    Poseida manufactures GMP allogeneic CAR-T in house for higher yields and lower COGS Facility supports current needs for three allogeneic programs while simultaneously advancing our platform POSEIDA'S ALLOGENEIC VS. AUTOLOGOUS PLANT 1​ • ~1/10 facility size for comparable output 2​ • Far lower labor

  60. Slide 60: Consistent platform reflecting systems engineering approach

    Poseida’s consistent platform reflects a holistic systems engineering approach to CAR-T set to deliver product after product Robust healthy donor screening system Non-viral gene insertion and gene editing “On-demand” delivery of therapy approaches the same across all programs, from inventory through

  61. Slide 61: Apheresis purity variable among donors but consistent

    NEW Apheresis purity is variable among donors but consistent between DATA collections Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3 100 100 100 Collection 1 Collection 1 Collec Collection 2 Collection 2 Collec Collection 3 Collection 3 Collec 50 50 50 0 0 0 Note: All cell types are % of CD45+ cell

  62. Slide 62: Fold expansion is donor-dependent

    NEW DATA Fold expansion during allogeneic CAR-T manufacturing is donor-dependent 20 15 There is significant donor variability in fold expansion 10 during CAR-T cell manufacturing 5 0 Lots/Donors 62 © 2024 Poseida Therapeutics, Inc. All Rights Reserved. Fold expansion

  63. Slide 63: Fold expansion consistent across collections from same donor

    NEW Fold expansion is consistent across multiple collections from the same DATA donor Donor Fold Expansion 25 Collection 1 20 • Donors had slightly differential levels Collection 2 of expansion but were overall within 15 Collection 3 a consistent and predictable range 10 • Donors had consistent expa

  64. Slide 64: Gene editing efficiency donor-dependent but consistent

    NEW DATA Gene editing efficiency is donor-dependent but consistent across collections 100 75 Pre-Purification CD3 KO and B2M 50 KO is donor-dependent 25 ⎯ Donor 1 and Donor 3 0 • ~80-90% (CD3 KO) Donor 1 Donor 1 Donor 2 Donor 3 • ~63-67% (B2M KO) ⎯ Donor 2 100 • ~68-75% (CD3 KO) Collection 1 80 Coll

  65. Slide 65: Final product phenotype donor-dependent but consistent

    NEW Final product phenotype is donor-dependent but consistent across multiple DATA collections Final Product CD8 Phenotype Final Product CD8 Phenotype 100 T EFF T EM T CM T SCM 50 0 65 © 2024 Poseida Therapeutics, Inc. All Rights Reserved. Donor 1, C1 Donor 1, C2 Donor 1, C3 Donor 2, C1 Donor 2, C2

  66. Slide 66: Final product potency donor-dependent but consistent

    NEW Final product potency is donor-dependent but consistent for an DATA individual donor In Vivo Potency 150 100 50 0 P-BCMA-ALLO1 Products • There is donor-dependent variability for in vivo anti-tumor potency ⎯ This potency is relatively consistent with repeat donor collections and productions ⎯ Mo

  67. Slide 67: Manufacturing platform delivers T SCM-rich products with high purity

    Poseida’s manufacturing platform, used across all products, delivers T -rich SCM products with high purity Manufacturing T Cell Isolation • Production process Non-viral Gene Editing Allogeneic dCas9 with preserves T phenotype SCM CAR-T Cell Selection and manufacturing process right gRNA Expansion wi

  68. Slide 68: Future manufacturing platform enhancement opportunities

    Future manufacturing platform enhancement opportunities Donor screening data is a ripe Gene editing is the most sensitive Poseida manufacturing processes space for cellular analysis via and critical element of the to date have used static expansion artificial intelligence. Advances in manufacturing

  69. Slide 69: Concluding remarks

    Concluding remarks Kristin Yarema, PhD President & CEO

  70. Slide 70: Partnerships with Roche and Astellas validate platform and fund programs

    Strong partnerships with Roche and Astellas validate allogeneic platform and fund programs • $50 million upfront plus up to $550 • Deal worth up to $6 billion in million, plus royalties aggregate value, plus royalties • Currently three heme malignancy • Combines Poseida allogeneic platform collabora

  71. Slide 71: Path to value creation in allogeneic cell therapy

    Poseida’s path to value creation in allogeneic cell therapy Presently heading into our second growth horizon Disrupt Cell Extend Therapy Approach Build Foundation DELIVER FOR PATIENTS DRIVE VALUE • Stream assets from allogeneic CAR- VALIDATE PLATFORM T product engine SCM • Enter autoimmune disease s

  72. Slide 72: Thank You

    Thank You To our patients, partners and dedicated Poseida teams for supporting our bold mission to redefine the future of cell therapy for life-threatening cancers and autoimmune diseases

  73. Slide 73: Q&A

    Q&A Type your question in the text box below

Poseida Therapeutics — Investor Day (November 2024) on 6ix